Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lawrence Otto Klein
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 68
- Beta
- -0.39
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 121.68
Financials
Net Income
$-41.21MEBITDA
$-50.06MFree Cash Flow
$-33.15MEPS (diluted)
$-0.66Shares Outstanding (diluted)
62.87M+149229.8%Operating Expenses
$50.06MCash & Debt
$873.56MDividend per Share
$19.36Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-105.43M | $-2.31 |
| 2024 | $0.00 | $-83.72M | $-4.99 |
| 2023 | $0.00 | $-5.34M | $-4.44 |
| 2022 | $0.00 | $-9.93M | $-8.27 |
| 2021 | $0.00 | $-19.32M | $-16.68 |
| 2020 | $0.00 | $-9.74M | $-8.40 |
| 2019 | $0.00 | $-5.48M | $-49.79 |
| 2018 | $0.00 | $-7.93M | $-123.73 |
| 2017 | $0.00 | $-18.49M | $-382.87 |
| 2016 | $0.00 | $-16.44M | $-390.96 |
| 2015 | $0.00 | $-11.45M | $-393.12 |
| 2014 | $0.00 | $-9.69M | $-710.64 |
| 2013 | $0.00 | $-6.94M | $-1572.48 |
| 2012 | $0.00 | $-4.32M | $-2933.25 |
Valuation
ORKAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-64.29%Social Signal Score
Mentions (7)
- Newszacks.com·11d ago·Neutral
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
View source ↗ - News (RSS)investing·12d ago·Neutral
Oruka Therapeutics stock falls despite positive trial data
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A data for all patients expected in December 202…
View source ↗ - Newszacks.com·38d ago·Positive
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
View source ↗ - Newsglobenewswire.com·42d ago·Neutral
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026.
View source ↗ - News (RSS)seekingalpha·56d ago·Negative
Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expected to begin in 1H 2027 ORCA-SURGE Week 16 data accelerated, now expected in 1Q 2027 ORCA-SPLASH, a Phase 2 trial of ORKA-002 in moderate-to-severe hidradenitis suppura
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.60 per share
Typical surprise +12.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.55 vs $-0.51miss
- Wed, May 13$-0.48 vs $-0.55beat
- Thu, Mar 12$-0.45 vs $-0.61beat
- Wed, Nov 12$-0.55 vs $-0.56beat
- Mon, Aug 11$-0.46 vs $-0.48beat
- Wed, May 14$-0.40 vs $-0.57beat
Estimates and results for ORKA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ORKA officers and directors.
- Bought
- —
- Sold
- $322.1m
0 trades
55 trades
- Klein Lawrence Ottosold
- Klein Lawrence Ottosold
- Klein Lawrence Ottosold
- Agarwal Arjunsold
- Quinlan Paul Tsold
- Quinlan Paul Tsold
- Quinlan Paul Tsold
- Quinlan Paul Tsold
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ORKA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.